In vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1
GENETICS · 2024
DOI: 10.1093/genetics/iyae139 ↗Kurz gefasst
Fachartikel in der Zeitschrift GENETICS, 2024. Verfasst von Jean-François Rivest und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre Hospitalier Universitaire de Québec Research Center and Faculty of Medicine, Laval University, Québec City, QC G1V 4G2, Canada. Hauptthemen laut MEDLINE: Tyrosinemias, CRISPR-Cas Systems, Gene Editing, Tyrosine. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Banting Research Foundation, Fonds de la recherche du Québec-Santé.
Abstract (Originalsprache)
Hereditary tyrosinemia type 1 is an autosomal recessive disorder caused by mutations (pathogenic variants) in fumarylacetoacetate hydrolase, an enzyme involved in tyrosine degradation. Its loss results in the accumulation of toxic metabolites that mainly affect the liver and kidneys and can lead to severe liver disease and liver cancer. Tyrosinemia type 1 has a global prevalence of approximately 1 in 100,000 births but can reach up to 1 in 1,500 births in some regions of Québec, Canada. Mutating functionally related “modifier’ genes (i.e. genes that, when mutated, affect the phenotypic impacts of mutations in other genes) is an emerging strategy for treating human genetic diseases. In vivo somatic genome editing in animal models of these diseases is a powerful means to identify modifier genes and fuel treatment development. In this study, we demonstrate that mutating additional enzymes in the tyrosine catabolic pathway through liver-specific genome editing can relieve or worsen the phenotypic severity of a murine model of tyrosinemia type 1. Neonatal gene delivery using recombinant adeno-associated viral vectors expressing Staphylococcus aureus Cas9 under the control of a liver-specific promoter led to efficient gene disruption and metabolic rewiring of the pathway, with systemic effects that were distinct from the phenotypes observed in whole-body knockout models. Our work illustrates the value of using in vivo genome editing in model organisms to study the direct effects of combining pathological mutations with modifier gene mutations in isogenic settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre Hospitalier Universitaire de Québec Research Center and Faculty of Medicine, Laval University, Québec City, QC G1V 4G2, Canada.
- Université Laval Cancer Research Centre, Québec City, QC G1V 0A6, Canada.
- Medical Genetics Service, Dept. Laboratory Medicine and Dept. Pediatrics, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC J1H 5N4, Canada.
- Centre Hospitalier Universitaire Sainte-Justine Research Center, Université de Montréal, Montréal, QC H3T 1C5, Canada.
ORCID-Profile: Jean-François Rivest, Paula J Waters, Yannick Doyon
Förderung
- CIHR
- Banting Research Foundation
- Fonds de la recherche du Québec-Santé
- Fondation du Grand défi Pierre Lavoie
- Groupe d'Aide aux Enfants Tyrosinémiques du Québec
- Fondation du CHU de Québec-Université Laval
- Canadian Institutes of Health Research
- Groupe d’Aide aux Enfants Tyrosinémiques du Québec
Zitieren
APA
Rivest, J. F., Carter, S., Goupil, C., Antérieux, P., Cyr, D., Ung, R. V., Dal Soglio, D., Mac-Way, F., Waters, P. J., Paganelli, M., & Doyon, Y. (2024). In vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1. GENETICS. https://doi.org/10.1093/genetics/iyae139
Vancouver
Rivest JF, Carter S, Goupil C, Antérieux P, Cyr D, Ung RV, et al. In vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1. GENETICS. 2024. doi:10.1093/genetics/iyae139
BibTeX
@article{Rivest2024,
author = {Rivest, Jean-François and Carter, Sophie and Goupil, Claudia and Antérieux, Pénélope and Cyr, Denis and Ung, Roth-Visal and Dal Soglio, Dorothée and Mac-Way, Fabrice and Waters, Paula J and Paganelli, Massimiliano and Doyon, Yannick},
title = {In vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1},
journal = {GENETICS},
year = {2024},
doi = {10.1093/genetics/iyae139}
}
EUVIMED